Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.10
CHE's Cash to Debt is ranked higher than
63% of the 293 Companies
in the Global Medical Care industry.

( Industry Median: 0.19 vs. CHE: 0.10 )
CHE' s 10-Year Cash to Debt Range
Min: 0.02   Max: 1.94
Current: 0.1

0.02
1.94
Equity to Asset 0.53
CHE's Equity to Asset is ranked higher than
81% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 0.41 vs. CHE: 0.53 )
CHE' s 10-Year Equity to Asset Range
Min: 0.39   Max: 0.59
Current: 0.53

0.39
0.59
Interest Coverage 20.50
CHE's Interest Coverage is ranked higher than
85% of the 168 Companies
in the Global Medical Care industry.

( Industry Median: 5.33 vs. CHE: 20.50 )
CHE' s 10-Year Interest Coverage Range
Min: 1.85   Max: 20.5
Current: 20.5

1.85
20.5
F-Score: 7
Z-Score: 6.62
M-Score: -2.17
WACC vs ROIC
8.82%
17.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 11.56
CHE's Operating margin (%) is ranked higher than
80% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 9.77 vs. CHE: 11.56 )
CHE' s 10-Year Operating margin (%) Range
Min: -2.6   Max: 11.56
Current: 11.56

-2.6
11.56
Net-margin (%) 6.82
CHE's Net-margin (%) is ranked higher than
81% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 4.94 vs. CHE: 6.82 )
CHE' s 10-Year Net-margin (%) Range
Min: -3.61   Max: 10.72
Current: 6.82

-3.61
10.72
ROE (%) 22.34
CHE's ROE (%) is ranked higher than
94% of the 282 Companies
in the Global Medical Care industry.

( Industry Median: 10.46 vs. CHE: 22.34 )
CHE' s 10-Year ROE (%) Range
Min: -5.58   Max: 22.06
Current: 22.34

-5.58
22.06
ROA (%) 11.46
CHE's ROA (%) is ranked higher than
93% of the 300 Companies
in the Global Medical Care industry.

( Industry Median: 4.18 vs. CHE: 11.46 )
CHE' s 10-Year ROA (%) Range
Min: -2.96   Max: 11.33
Current: 11.46

-2.96
11.33
ROC (Joel Greenblatt) (%) 169.16
CHE's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 20.34 vs. CHE: 169.16 )
CHE' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12.54   Max: 189.5
Current: 169.16

-12.54
189.5
Revenue Growth (3Y)(%) 8.00
CHE's Revenue Growth (3Y)(%) is ranked higher than
76% of the 237 Companies
in the Global Medical Care industry.

( Industry Median: 8.30 vs. CHE: 8.00 )
CHE' s 10-Year Revenue Growth (3Y)(%) Range
Min: -18.9   Max: 42.9
Current: 8

-18.9
42.9
EBITDA Growth (3Y)(%) 9.20
CHE's EBITDA Growth (3Y)(%) is ranked higher than
79% of the 188 Companies
in the Global Medical Care industry.

( Industry Median: 6.80 vs. CHE: 9.20 )
CHE' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -31.3   Max: 52.3
Current: 9.2

-31.3
52.3
EPS Growth (3Y)(%) 10.80
CHE's EPS Growth (3Y)(%) is ranked higher than
76% of the 178 Companies
in the Global Medical Care industry.

( Industry Median: 10.30 vs. CHE: 10.80 )
CHE' s 10-Year EPS Growth (3Y)(%) Range
Min: -15.4   Max: 56.8
Current: 10.8

-15.4
56.8
» CHE's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CHE Guru Trades in Q1 2014

David Dreman 565 sh (New)
Jeremy Grantham 33,147 sh (New)
Jim Simons 39,219 sh (New)
Joel Greenblatt 295,553 sh (+7.78%)
Chuck Royce 1,504,885 sh (+4.27%)
John Hussman 61,000 sh (unchged)
Richard Pzena 347,051 sh (-4.22%)
Mario Gabelli 823,015 sh (-6.66%)
John Keeley 22,500 sh (-22.17%)
» More
Q2 2014

CHE Guru Trades in Q2 2014

Jim Simons 82,100 sh (+109.34%)
John Hussman 125,000 sh (+104.92%)
Mario Gabelli 835,425 sh (+1.51%)
Jeremy Grantham Sold Out
David Dreman Sold Out
John Keeley 21,400 sh (-4.89%)
Chuck Royce 1,306,738 sh (-13.17%)
Richard Pzena 281,109 sh (-19.00%)
Joel Greenblatt 201,109 sh (-31.96%)
» More
Q3 2014

CHE Guru Trades in Q3 2014

Ken Fisher 530,910 sh (New)
Jim Simons 89,800 sh (+9.38%)
John Keeley 21,400 sh (unchged)
Richard Pzena Sold Out
Mario Gabelli 793,833 sh (-4.98%)
Joel Greenblatt 159,963 sh (-20.46%)
John Hussman 84,000 sh (-32.80%)
Chuck Royce 746,776 sh (-42.85%)
» More
Q4 2014

CHE Guru Trades in Q4 2014

Jim Simons 105,800 sh (+17.82%)
Ken Fisher 570,040 sh (+7.37%)
John Hussman 84,000 sh (unchged)
Chuck Royce 481,654 sh (unchged)
Chuck Royce 481,654 sh (unchged)
John Keeley 20,600 sh (-3.74%)
Mario Gabelli 748,686 sh (-5.69%)
Chuck Royce 362,654 sh (-51.44%)
Joel Greenblatt 32,701 sh (-79.56%)
» More
» Details

Insider Trades

Latest Guru Trades with CHE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Chemed Corp

Mario Gabelli Comments on Chemed Corp. - Jan 29, 2014

Chemed Corp. (CHE)(0.3%) (CHE - $76.62 - NYSE) , based in Cincinnati, OH, is a holding company that owns the Vitas hospice company and the Roto Rooter plumbing business. Vitas is the nation's largest hospice company, with almost $1 billion in annual sales. The company is currently facing headwinds from government billing changes and a regulatory investigation, but its management is working hard to protect margins and it should begin to move beyond these issues in 2014. Roto Rooter is enjoying steady revenue growth and record profitability as the economy, particularly the housing market, improves. With strong free cash flow and modest capital expenditures, Chemed is returning the vast majority of its cash flow to shareholders via significant share repurchases.

 

From Mario Gabelli (Trades, Portfolio)’s Gabelli Asset Fund fourth quarter 2013 commentary.

Check out Mario Gabelli latest stock trades

Ratios

vs
industry
vs
history
P/E(ttm) 21.50
CHE's P/E(ttm) is ranked higher than
86% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 47.20 vs. CHE: 21.50 )
CHE' s 10-Year P/E(ttm) Range
Min: 10.7   Max: 41.64
Current: 21.5

10.7
41.64
Forward P/E 16.92
CHE's Forward P/E is ranked higher than
88% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 31.06 vs. CHE: 16.92 )
N/A
PE(NRI) 21.60
CHE's PE(NRI) is ranked higher than
88% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 45.40 vs. CHE: 21.60 )
CHE' s 10-Year PE(NRI) Range
Min: 10.72   Max: 52.26
Current: 21.6

10.72
52.26
P/B 4.60
CHE's P/B is ranked higher than
62% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 3.10 vs. CHE: 4.60 )
CHE' s 10-Year P/B Range
Min: 1.83   Max: 5.08
Current: 4.6

1.83
5.08
P/S 1.50
CHE's P/S is ranked higher than
74% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.80 vs. CHE: 1.50 )
CHE' s 10-Year P/S Range
Min: 0.67   Max: 1.72
Current: 1.5

0.67
1.72
PFCF 31.30
CHE's PFCF is ranked higher than
75% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 50.30 vs. CHE: 31.30 )
CHE' s 10-Year PFCF Range
Min: 7.11   Max: 81.56
Current: 31.3

7.11
81.56
POCF 19.25
CHE's POCF is ranked higher than
74% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 19.26 vs. CHE: 19.25 )
CHE' s 10-Year POCF Range
Min: 5.92   Max: 29.68
Current: 19.25

5.92
29.68
EV-to-EBIT 12.97
CHE's EV-to-EBIT is ranked higher than
91% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 25.02 vs. CHE: 12.97 )
CHE' s 10-Year EV-to-EBIT Range
Min: 6.9   Max: 38
Current: 12.97

6.9
38
PEG 2.32
CHE's PEG is ranked higher than
94% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CHE: 2.32 )
CHE' s 10-Year PEG Range
Min: 0.31   Max: 5.41
Current: 2.32

0.31
5.41
Shiller P/E 27.70
CHE's Shiller P/E is ranked higher than
87% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 197.29 vs. CHE: 27.70 )
CHE' s 10-Year Shiller P/E Range
Min: 15.79   Max: 137.8
Current: 27.7

15.79
137.8
Current Ratio 0.99
CHE's Current Ratio is ranked higher than
65% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 1.34 vs. CHE: 0.99 )
CHE' s 10-Year Current Ratio Range
Min: 0.62   Max: 1.88
Current: 0.99

0.62
1.88
Quick Ratio 0.96
CHE's Quick Ratio is ranked higher than
66% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 1.15 vs. CHE: 0.96 )
CHE' s 10-Year Quick Ratio Range
Min: 0.6   Max: 1.79
Current: 0.96

0.6
1.79
Days Inventory 2.31
CHE's Days Inventory is ranked higher than
96% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 42.45 vs. CHE: 2.31 )
CHE' s 10-Year Days Inventory Range
Min: 2.27   Max: 68.23
Current: 2.31

2.27
68.23
Days Sales Outstanding 31.23
CHE's Days Sales Outstanding is ranked higher than
90% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 52.21 vs. CHE: 31.23 )
CHE' s 10-Year Days Sales Outstanding Range
Min: 16.34   Max: 56.06
Current: 31.23

16.34
56.06

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.70
CHE's Dividend Yield is ranked lower than
82% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 1.44 vs. CHE: 0.70 )
CHE' s 10-Year Dividend Yield Range
Min: 0.35   Max: 1.2
Current: 0.7

0.35
1.2
Dividend Payout 0.15
CHE's Dividend Payout is ranked higher than
97% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CHE: 0.15 )
CHE' s 10-Year Dividend Payout Range
Min: 0.08   Max: 1.15
Current: 0.15

0.08
1.15
Dividend growth (3y) 11.90
CHE's Dividend growth (3y) is ranked higher than
79% of the 121 Companies
in the Global Medical Care industry.

( Industry Median: 12.70 vs. CHE: 11.90 )
CHE' s 10-Year Dividend growth (3y) Range
Min: -42.4   Max: 35.7
Current: 11.9

-42.4
35.7
Yield on cost (5-Year) 1.53
CHE's Yield on cost (5-Year) is ranked lower than
56% of the 189 Companies
in the Global Medical Care industry.

( Industry Median: 1.83 vs. CHE: 1.53 )
CHE' s 10-Year Yield on cost (5-Year) Range
Min: 0.77   Max: 2.63
Current: 1.53

0.77
2.63
Share Buyback Rate 5.20
CHE's Share Buyback Rate is ranked higher than
97% of the 191 Companies
in the Global Medical Care industry.

( Industry Median: -1.50 vs. CHE: 5.20 )
CHE' s 10-Year Share Buyback Rate Range
Min: 6.9   Max: -10.2
Current: 5.2

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.20
CHE's Price/DCF (Projected) is ranked higher than
89% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 5.00 vs. CHE: 1.20 )
CHE' s 10-Year Price/DCF (Projected) Range
Min: 0.59   Max: 2.09
Current: 1.2

0.59
2.09
Price/Median PS Value 1.40
CHE's Price/Median PS Value is ranked higher than
66% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 1.38 vs. CHE: 1.40 )
CHE' s 10-Year Price/Median PS Value Range
Min: 0.52   Max: 1.67
Current: 1.4

0.52
1.67
Price/Peter Lynch Fair Value 2.30
CHE's Price/Peter Lynch Fair Value is ranked higher than
91% of the 328 Companies
in the Global Medical Care industry.

( Industry Median: 0.00 vs. CHE: 2.30 )
CHE' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.56   Max: 2.04
Current: 2.3

0.56
2.04
Earnings Yield (Greenblatt) 7.60
CHE's Earnings Yield (Greenblatt) is ranked higher than
89% of the 299 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. CHE: 7.60 )
CHE' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.6   Max: 14.5
Current: 7.6

2.6
14.5
Forward Rate of Return (Yacktman) 13.48
CHE's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 204 Companies
in the Global Medical Care industry.

( Industry Median: 11.46 vs. CHE: 13.48 )
CHE' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -16.5   Max: 60.1
Current: 13.48

-16.5
60.1

Business Description

Industry: Health Care Providers » Medical Care
Compare:FMS, DVA, FSNUY, BDUUF, SKHCY » details
Traded in other countries:CXM.Germany,
Chemed Corp was incorporated in Delaware in 1970. The Company conducts its business operations in two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). VITAS Healthcare Corporation provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers. Roto-Rooter provides plumbing and drain cleaning services to both residential and commercial customers. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 109 leased and owned office and service facilities in 30 states. VITAS operate 51 programs from 154 leased facilities and 37 inpatient units in 18 states and the District of Columbia. The Company faces competition from sewer, drain and pipe cleaning, excavation and plumbing repair businesses and is fragmented, with the bulk of the industries consisting of local and regional competitors. VITAS competes with a number of national and regional hospice providers, including Gentiva Health Services, Inc., hospitals, nursing homes, home health agencies and other health care providers. The Company is subject to federal, state and local laws and regulations relating to franchising, insurance and other aspects of business.
» More Articles for CHE

Headlines

Articles On GuruFocus.com
Mario Gabelli Comments on Chemed Corp. Jan 29 2014 
The Gabelli Asset Fund Shareholder Commentary - Fourth Quarter 2013 Jan 29 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
comment on CHE May 07 2013 
comment on CHE May 07 2013 
Chemed Corporation: Fundamental Stock Research Analysis Jan 29 2013 
12 Healthcare Dividend Stocks With Highest Short Float Ratio Jun 02 2012 
hospice, roto rooter Jan 11 2012 
9 Dividend Stocks Raising Their Yield On Cost Aug 15 2011 
Guru Stocks Raising Dividends: THO, ACU, KAMN, PRIM, CHE Aug 15 2011 

More From Our Partners
Almost Family (AFAM) Jumps: Stock Rises 6.1% - Tale of the Tape Mar 31 2015 - ZACKS

More From Other Websites
Almost Family (AFAM) Jumps: Stock Rises 6.1% - Tale of the Tape Mar 31 2015
MERGER PROPOSAL - DESPATCH OF THE HUTCHISON SCHEME DOCUMENT AND DESPATCH OF THE CKH HOLDINGS... Mar 30 2015
MERGER PROPOSAL - BOOK CLOSURE PERIOD FOR DETERMINING ENTITLEMENT TO ATTEND AND VOTE AT THE EGM Mar 27 2015
China Cord Blood (CO) Worth Watching: Stock Gains 7.3% - Tale of the Tape Mar 24 2015
Is Chemed (CHE) Stock a Solid Choice Right Now? - Tale of the Tape Mar 19 2015
Omnicell Tweaks '15 View on Legal Issues, Impending Buyout - Analyst Blog Mar 18 2015
Integra (IART) Rides High on Solid Q4, DuraSeal Product Line - Analyst Blog Mar 18 2015
FULFILMENT OF (1) A CONDITION PRECEDENT TO COMPLETION OF THE HUSKY SHARE EXCHANGE; AND (2) THE... Mar 18 2015
SPIN-OFF PROPOSAL – PROPOSED SPIN-OFF AND SEPARATE LISTING OF CHEUNG KONG PROPERTY HOLDINGS... Mar 17 2015
CHEMED CORP Files SEC form 8-K, Other Events Mar 13 2015
Chemed Corporation’s Board of Directors Authorizes an Additional $100 Million for Stock Repurchase Mar 13 2015
Chemed Corporation’s Board of Directors Authorizes an Additional $100 Million for Stock Repurchase Mar 13 2015
FORMAL NOTICE – LISTING BY WAY OF INTRODUCTION OF THE ENTIRE ISSUED SHARE CAPITAL OF CK HUTCHISON... Mar 13 2015
Quest Diagnostics' New Pediatric Neurological Disorder Test - Analyst Blog Mar 12 2015
AmSurg Boosts Radiology Services with Buyout in Florida - Analyst Blog Mar 11 2015
Wednesday's Swing Set Ups Mar 11 2015
Chemed Corporation to Present at the Barclays Capital 2015 Global Healthcare Conference Mar 09 2015
Chemed Corporation to Present at the Barclays Capital 2015 Global Healthcare Conference Mar 09 2015
Amedisys Q4 Earnings in Line, Revenues Miss the Mark - Analyst Blog Mar 09 2015
DaVita's (DVA) Inorganic Growth Strategy Looks Promising - Analyst Blog Mar 06 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK